|
|
|
|
||
|
||
|
Vol. 8, Nos. 1-50 pp. 1-1650 Jan. 1 - Dec. 31, 2010 A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
ZETIA
– Anticholestoral drug patent (D.N.J.), 553; settlement, 622
– Generic, 603
– Cholesterol drug and rhabdomyolysis, 400
– Bone drug infringement suit (D. Del.), 982
– Fibromyalgia drug, FDA panel rejection, 1117
– Actinic keratose treatment approval, 431
– Asthma drug ads, FDA letter, 899
– Conjunctivitis patent invalid (D. Del.), 851
– Antipsychotic off-label use settlement (E.D.N.Y.), 488
– Diabetes suit, no summary judgment (E.D.N.Y.), 62 – Discovery documents, release barred (2nd Cir.), 1145 – Learned intermediary (2nd Cir.), 948 – Overpayments class decertified (2nd Cir.), 1217 – Time-barred suit (E.D.N.Y.), 184 – Trademark, counterfeiting conviction vacated (5th Cir.), 320 – Unapproved uses, Miss. settlement (Miss. Cir. Ct.), 204 – Validity of patent, rehearing ordered (Fed. Cir.), 1036 Contact the Webmaster at webmaster@bna.com Copyright © The Bureau of National Affairs, Inc. All Rights Reserved. |
